SREBF1 and fatty liver disease: Significantly improves liver steatosis and fibrosis; specifically targets and inhibits DGAT2, inhibiting triglyceride synthesis at the ER-Lipid Droplet contact site and feedback regulating SREBP-1c via PE levels